187 related articles for article (PubMed ID: 20035679)
41. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
42. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
Ferl GZ; Wu AM; DiStefano JJ
Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
[TBL] [Abstract][Full Text] [Related]
43. [The pharmacokinetics of monoclonal antibodies].
Keizer RJ; Huitema AD; Damen CW; Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2007 Mar; 151(12):683-8. PubMed ID: 17447593
[TBL] [Abstract][Full Text] [Related]
44. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
Haraya K; Tachibana T; Nanami M; Ishigai M
Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
[TBL] [Abstract][Full Text] [Related]
45. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
47. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
48. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Challa DK; Velmurugan R; Ober RJ; Sally Ward E
Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
[TBL] [Abstract][Full Text] [Related]
49. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.
Richter WF; Christianson GJ; Frances N; Grimm HP; Proetzel G; Roopenian DC
MAbs; 2018 Jul; 10(5):803-813. PubMed ID: 29621428
[TBL] [Abstract][Full Text] [Related]
50. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis.
Maidji E; McDonagh S; Genbacev O; Tabata T; Pereira L
Am J Pathol; 2006 Apr; 168(4):1210-26. PubMed ID: 16565496
[TBL] [Abstract][Full Text] [Related]
51. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement.
Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW
J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417
[TBL] [Abstract][Full Text] [Related]
52. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
Ternant D; Arnoult C; Pugnière M; Dhommée C; Drocourt D; Perouzel E; Passot C; Baroukh N; Mulleman D; Tiraby G; Watier H; Paintaud G; Gouilleux-Gruart V
J Immunol; 2016 Jan; 196(2):607-13. PubMed ID: 26685205
[TBL] [Abstract][Full Text] [Related]
53. Nonclassical major histocompatibility complex I-like Fc neonatal receptor (FcRn) expression in neonatal human tissues.
Cianga C; Cianga P; Plamadeala P; Amalinei C
Hum Immunol; 2011 Dec; 72(12):1176-87. PubMed ID: 21978715
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions.
Getman KE; Balthasar JP
J Pharm Sci; 2005 Apr; 94(4):718-29. PubMed ID: 15682382
[TBL] [Abstract][Full Text] [Related]
55. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
[TBL] [Abstract][Full Text] [Related]
56. Fc-dependent mechanisms of action: roles of FcγR and FcRn.
Kuijpers T
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):89-91. PubMed ID: 25546775
[No Abstract] [Full Text] [Related]
57. IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R.
Martin CE; van Leeuwen EM; Im SJ; Roopenian DC; Sung YC; Surh CD
Blood; 2013 May; 121(22):4484-92. PubMed ID: 23610371
[TBL] [Abstract][Full Text] [Related]
58. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
59. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
60. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
